Personalized medicine for cats with heart disease

Personalized medicine for cats with heart disease
UC Davis veterinarians identified Lizard, the cat pictured above, as having hypertrophic cardiomyopathy, a heart disease that affects 1 in 7 cats. He was part of the study examining how a cat’s DNA alters how it responds to a commonly prescribed medication to prevent blood clots in cats with HCM. Credit: UC Davis School of Veterinary Medicine

Veterinarians at the University of California, Davis, have found that a cat's DNA alters how it responds to a life-saving medication used to treat hypertrophic cardiomyopathy, or HCM, a heart disease that affects 1 in 7 cats. The study was published in the journal Scientific Reports.

HCM causes a cat's heart muscle to thicken. As the condition worsens, cats can form clots in their hearts that may later dislodge and cause extreme pain, distress and even sudden death. Clopidogrel, or Plavix, is one of the most commonly prescribed medications used to prevent blood clots in cats with HCM.

"We were consistently seeing cats, that despite being on , were still forming blood clots," said corresponding author Josh Stern, professor of veterinary cardiology and geneticist with the UC Davis School of Veterinary Medicine. This led Stern and the research team to begin research in this area and identify mutations in the drug pathway that looked important. Data showed that nearly 20% of cats had resistance to the clopidogrel therapy, which is widely used by practitioners all over the world.

"This study was about figuring out why some cats weren't responding as expected to clopidogrel therapy and leading us towards a more effective prescription," Stern said.

Simple genetic test

Researchers began a clinical trial on cats with HCM. They first tested the cats' ability to form blood clots. The cats' owners administered clopidogrel for 14 days, and the cats were tested again. Researchers were then able to test whether that they had identified within the drug pathway were responsible for reducing the drug's effectiveness.

"The end result is the ability to use a simple genetic test to make an educated decision about which drug therapy may be best for preventing in cats with HCM," Stern said.

While testing like this is not yet commercially available, researchers hope that eventually veterinarians will be able to rapidly test cats with HCM for these mutations as they are making prescribing decisions.

"We are very excited to be approaching this era where personalized or precision medicine in animals can catch up to in humans," said co-author Ronald Li, an assistant professor of veterinary emergency and and coagulation researcher, whose lab conducted much of the functional testing of the anticoagulant therapies. "Just as we can't expect every human to respond to medication in the same way, we can't expect all cats to respond the same way either."

Researchers are hoping that in the future, personalized medicine for cats would allow veterinarians to test kittens for a whole host of genetic variants that would help inform medical decisions and treatments as they grow and require veterinary care.

More information: Yu Ueda et al, A genetic polymorphism in P2RY1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy, Scientific Reports (2021). DOI: 10.1038/s41598-021-91372-3

Journal information: Scientific Reports

Provided by UC Davis

Citation: Personalized medicine for cats with heart disease (2021, July 6) retrieved 21 September 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New drug for heart disease shows promise for cats and humans


Feedback to editors